RESUMO
A case-control study was carried out on a sample of 15 Mexican patients (40-56 years old) with type 2 diabetes mellitus (DM2) that had developed five years and been treated with oral hypoglycemic drugs (sulfonylurea and/or metformin), with no microvascular or macrovascular complications. The aim of this study was to assess whether Mexican patients with DM2 differed from a control group in the frequency of micronuclei (MN). A control group of 10 individuals without DM2 (38-54 years old) was included. The frequency of MN in binucleated lymphocytes was analyzed according to the Fenech criteria. At time being this investigation should be considered as a preliminary study in which the influence of potential confounders cannot be adequately assessed. However, our result showed a MN frequency significant increase in DM2 patients (6.53 +/- 2.03 per 1000 cells) relative to that of the control group (3.10 +/- 1.79 per 1000 cells). MN may constitute a possible component of a panel of biomarkers for the risk of DM2. This cytogenetic damage also indicates an enhanced risk of cancer, as has been found in previous studies. These results should be validated by other researchers.
Assuntos
Diabetes Mellitus Tipo 2/genética , Micronúcleos com Defeito Cromossômico , Adulto , Idoso , Diabetes Mellitus Tipo 2/tratamento farmacológico , Feminino , Humanos , Masculino , México , Testes para Micronúcleos , Pessoa de Meia-IdadeRESUMO
Glucocorticoids inhibit insulin expression in cultured pancreatic islet cells. In this study, we provide evidence that transcriptional downregulation of insulin gene expression by glucocorticoids is the result of synergistic interaction between various elements of the insulin promoter. Similar synergistic effects on insulin gene transcription were previously reported for other key insulin regulators, cyclic adenosine monophosphate (cAMP) and glucose. Transfection of CAT constructs containing different segments of the insulin promoter into the pancreatic cell line, HIT T-15 2.2.2, demonstrated that dexamethasone decreased CAT activity in all constructs tested. However, differences were found in the relative sensitivities of the various constructs. Glucocorticoid inhibition of expression from plasmids containing A elements may result from decreased expression of the pancreatic homeodomain protein STF-1. However, a different mechanism must be invoked for insulin promoter constructs lacking A sites, which nevertheless still demonstrated negative regulation. Glucocorticoid-induced inhibition of one of these regions (-882 to -342) was seen to require pancreas-specific factors, because inhibition was observed in HIT T-15 2.2.2 cells but not in the nonpancreatic COS-1 cells. We conclude, therefore, that the human insulin gene contains multiple transcriptional elements that respond to glucocorticoids, some of which require beta cell-specific factors.